INTERVALS: Access The Science Behind Safer Smoking
Philip Morris International (PMI) has shared details of its toxicology data sharing platform INTERVALS at the recent Society of Toxicology Annual Meeting in Baltimore, MD, USA.1 The presentation of INTERVALS, an inhalation toxicology repository for Reduced-Risk Products (RRPs)*, took place during a session hosted by the Institute of In Vitro Sciences exploring best practices and standards in toxicological data sharing. The session was attended by world-leading toxicologists, safety assessment specialists and representatives from the tobacco industry.
“The INTERVALS initiative shows just how seriously PMI is taking the need to have its methodologies and data verified by the external community,” said Dr A. Wallace Hayes, University of South Florida and Michigan State University. “The data are presented in such a way that they are truly accessible, understandable and reusable. What’s also impressive is just how much information is available, everything from the finest details of experimental protocols through to complete, uncensored research datasets. It is my hope that others will take up the challenge by carefully examining the methods and results either to corroborate or refute them. Not only does their approach illustrate the extent to which PMI has changed with regard to openness and transparency, it is also unique within the scientific community in general.”
The INTERVALS proof-of-concept website hosts comprehensive, annotated datasets that have been generated by PMI as part of their development and assessment of RRPs, products with the potential to present less risk of harm to smokers who switch to them as compared to continued cigarette smoking. It has been designed to facilitate the practical reuse of methods and data, and thus to demonstrate the reproducibility of scientific findings. It is hoped that other industries and institutions producing data relevant to RRPs will submit that data to an improved version of the INTERVALS platform to be released at the end of the year for the benefit of the wider community. A comprehensive overview of INTERVALS, describing the rationale for the project and its data practices, has also been published on F1000Research, a transparent publishing platform with no editorial bias, open peer review, and the mandatory inclusion of all source data with submitted papers.2
1. Boué S. 2017. Supporting evidence-based analysis for novel tobacco and alternative products through a toxicology data-sharing infrastructure. IIVS Spotlight: Standards and transparency in toxicology testing. Society of Toxicology Annual Meeting, Baltimore, MD, USA. Wednesday, March 15th.
2. Boué S, et al. 2017. Supporting evidence-based analysis for modified risk tobacco products through a toxicology data-sharing infrastructure. F1000Research, 6:12 DOI: http://dx.doi.org/10.12688/f1000research.10493.1
This article has been republished from materials provided by INTERVALS. Note: material may have been edited for length and content. For further information, please contact the cited source.
Targeted Drug Could be Used to Treat Advanced Cancers Located Anywhere in the BodyNews
A new targeted drug could be used to treat a small number of advanced cancers no matter where they grow in the body.READ MORE
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE